open access

Vol 16, No 2 (2009)
How to do
Published online: 2009-01-06
Get Citation

Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies

Leszek Bryniarski, Agnieszka Pelc-Nowicka, Michał Zabojszcz, Ewa Mirek-Bryniarska
Cardiol J 2009;16(2):179-189.

open access

Vol 16, No 2 (2009)
How to do
Published online: 2009-01-06

Abstract

Dual antiplatelet therapy is currently recommended for all patients with acute coronary syndromes, independent of whether they receive pharmacological treatment or undergo percutaneous coronary intervention. Antiplatelet agents are the cornerstone of pharmacological treatment in interventional cardiology. However, there is a clear need for randomized trials to assess the treatment strategy of dual antiplatelet therapy in patients who also need long-term antithrombotic treatment (such as those with atrial fibrillation, prosthetic heart valve, mitral valve regurgitation or stenosis, deep vein thrombosis, pulmonary embolism, or pulmonary hypertension). In this paper we discuss trials and analyses on the use of dual antiplatelet treatment in combination with antithrombotic therapy in particular diseases, with a focus on the risk of hemorrhagic events connected with this treatment, as well as recent guidelines of the European Society of Cardiology, the American College of Cardiology, and the American Heart Association.

Abstract

Dual antiplatelet therapy is currently recommended for all patients with acute coronary syndromes, independent of whether they receive pharmacological treatment or undergo percutaneous coronary intervention. Antiplatelet agents are the cornerstone of pharmacological treatment in interventional cardiology. However, there is a clear need for randomized trials to assess the treatment strategy of dual antiplatelet therapy in patients who also need long-term antithrombotic treatment (such as those with atrial fibrillation, prosthetic heart valve, mitral valve regurgitation or stenosis, deep vein thrombosis, pulmonary embolism, or pulmonary hypertension). In this paper we discuss trials and analyses on the use of dual antiplatelet treatment in combination with antithrombotic therapy in particular diseases, with a focus on the risk of hemorrhagic events connected with this treatment, as well as recent guidelines of the European Society of Cardiology, the American College of Cardiology, and the American Heart Association.
Get Citation

Keywords

antiplatelet therapy; antithrombotic treatment; acetylsalicylic acid; clopidogrel; oral anticoagulants; acute coronary syndromes; atrial fibrillation

About this article
Title

Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies

Journal

Cardiology Journal

Issue

Vol 16, No 2 (2009)

Pages

179-189

Published online

2009-01-06

Bibliographic record

Cardiol J 2009;16(2):179-189.

Keywords

antiplatelet therapy
antithrombotic treatment
acetylsalicylic acid
clopidogrel
oral anticoagulants
acute coronary syndromes
atrial fibrillation

Authors

Leszek Bryniarski
Agnieszka Pelc-Nowicka
Michał Zabojszcz
Ewa Mirek-Bryniarska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl